RE: [Dev-C++] AFTER-HOURS TRADING - Breaking News...kimball

[Paz, N. <Nan...@mp...>]

Please unsubscribe me.

>-----Original Message-----
>From: dev...@li... [mailto:dev-cpp-users=
-
>ad...@li...] On Behalf Of Dana Gibbons
>Sent: Thursday, December 04, 2003 8:38 AM
>To: mpe...@li...
>Cc: dev...@li...
>Subject: [Dev-C++] AFTER-HOURS TRADING - Breaking News...kimball
>
>AFTER-HOURS TRADING - BREAKING NEWS
>
>Get Quote - http://quote.money.cnn.com/quote/quote?symbols=3Dhtds
>
>Hard to Treat Diseases Incorporated - HTDS - Announces: Receipt of
Tubercin
>Toxicity Study and Formation of Scientific Advisory Panel - Wednesday=

>December 3, 8:04 pm ET
>
>DELRAY BEACH, Fla.--(BUSINESS WIRE)--Dec. 3, 2003--Hard to Treat
Diseases
>Incorporated (Pink Sheets: HTDS) announces today that the spokesperso=
n
for
>the independent medical group conducting the testing for HTTD (HTDS)
has
>forwarded the formal Testing Results of Tubercin(r)'s Toxicity Trials=

to
>HTTD.
>
>Tubercin of five different concentrations was administered to five
groups
>of mice. A pathologist at the University of Oklahoma Health Science
Center
>performed autopsies. The mice were randomized and only the control
mouse
>was known to the pathologist, as stated in the cover letter of the
>Pathology Report.
>
>The report concludes, "All tissues evaluated, visceral organs and the=

brain
>were essentially normal in appearance." "The importance of this repor=
t
is
>even better than I expected," stated the spokesperson for the medical=

>group. "As the testing continues and if the results are similar to
those of
>Chemotherapy and or radiation with no harmful side effects, Tubercin
has
>enormous potential for the treatment of cancer and the immune system.=
"
>
>The President and CEO of HTTD, Mr. Colm J. King is in the process of
>forming a Scientific Advisory Panel with leading Oncologists and
>Immunologists from prestigious institutions in the U.S. The panel wil=
l
>review the reports and results of Tubercin(r)'s findings and will
report back
>to Mr. King with the ongoing reports in layman language for the
>shareholders.
>
>"We are continuing to receive promising results regarding Tubercin(r)=

and
>we're looking forward to additional positive results in the near
future,"
>stated Mr. King. "These tests prove that Tubercin(r) is non-toxic and=

is the
>first step on the way to human clinical trials as well as the first
>positive breakthrough conducted in the United States with an
independent
>medical group for Tubercin(r).
>
>Operating out of Delray Beach, Florida, Hard to Treat Diseases
Incorporated
>("HTTD") holds the international marketing rights, except South Korea=
,
to
>Tubercin(r), a patented immunostimulant developed for combating Cance=
r
under
>medical patent (US Patent 6,274,356). The unique properties unlike
other
>cancer products are clearly stated in the abstract summary of the
patent...
>"A carbohydrate complex, which is a mixture of low molecular-weight
>polysaccharides of an arabinomannan structure extracted from
Mycobacterium
>tuberculosis, is highly effective in treating various cancer patients=

>without incurring any adverse side effects."
>
>
>
>
>
>
>Statements in this press release that are not historical facts are
forward-
>looking statements within the meaning of the Securities Act of 1933, =
as
>amended. Those statements include statements regarding the intent,
belief
>or current expectations of the Company and its management. Such
statements
>reflect management's current views, are based on certain assumptions
and
>involve risks and uncertainties. Actual results, events, or performan=
ce
may
>differ materially from the above forward-looking statements due to a
number
>of important factors, and will be dependent upon a variety of factors=
,
>including, but not limited to, our ability to obtain additional
financing
>and access funds from our existing financing arrangements that will
allow
>us to continue our current and future operations and whether demand f=
or
our
>product and testing service in domestic and international markets wil=
l
>continue to expand. The Company undertakes no obligation to publicly
update
>these forward-looking statements to reflect events or circumstances
that
>occur after the date hereof or to reflect any change in the Company's=

>expectations with regard to these forward-looking statements or the
>occurrence of unanticipated events.
>
>
>
>
>
>
>
>
>
>
>
>
>
>
>
>
>
>
>
>
>
>
>
>
>
>
>
>bsktqg yx  ojbs
>snlta
>ag gvtuplhwqhuxrle syk h wxjql aqshdoqcwqvosasjgk
>ljf ra



This e-mail, including any attachments, is a confidential business com=
munication, and may contain information that is confidential, propriet=
ary and/or privileged.  This e-mail is intended only for the individua=
l(s) to whom it is addressed, and may not be saved, copied, printed, d=
isclosed or used by anyone else.  If you are not the(an) intended reci=
pient, please immediately delete this e-mail from your computer system=
 and notify the sender.  Thank you.